Eyal Amiel, Trudeau Institute Eyal Amiel, Trudeau Institute
"Improving Anti-tumor Vaccine Efficacy by Modulating Dendritic Cell Metabolism"
4:00 p.m.
CNS 112
Department Seminar Series
Download the PDF announcement here.
Refreshments served at 3:45, 1st floor CNS foyer. Bring your mug. Reduce, Reuse, Recycle.
Individuals with disabilities requiring accommodations should contact Nancy Pierce at 274-3161. We ask that requests for accommodations be made as soon as possible.
In vitro generated Dendritic cells (DCs) are currently being tested in clinical trials for cell vaccine therapies in cancer treatment. The short lifespan of DCs following their activation is a major hurdle of DC vaccine therapeutic approaches. Recent reports demonstrate that genetic modulation DC longevity can improve the potency of DC vaccines in animal tumor models. In this work, we assess the role of mTOR inhibition in regulating DC lifespan and activation, and assessing whether this approach can improve the efficacy of autologous DC vaccination in establishing anti-tumor immunity. Our data demonstrate that mTOR inhibition improves survival of activated DCs and prolongs expression of co-stimulatory molecules on these cells. Furthermore, autologous DC vaccination with rapamycin-treated DCs results in improved generation of anti-tumor immunity compared to conventionally activated DCs.
https://www.ithaca.edu/intercom/article.php/20110922151809972